Cells were treated with 10−8 M to 10−6 M testosterone (T, Cat no. 86500; Sigma-Aldrich, St. Louis, MO, USA) or anti-androgens 10−4 M hydroxyflutamide (HF; Cat no. H4166; Sigma-Aldrich) or 10−6 M bicalutamide (Bic) (Cat no. B9061; Sigma-Aldrich) alone or with the addition of 10
Bicalutamide bic
Bicalutamide (Bic) is a lab equipment product manufactured by Merck Group. It is a nonsteroidal anti-androgen used for the treatment of prostate cancer. Bicalutamide competitively inhibits the action of androgens by binding to androgen receptors.
Lab products found in correlation
3 protocols using bicalutamide bic
Sertoli Cell Line Characterization
Cells were treated with 10−8 M to 10−6 M testosterone (T, Cat no. 86500; Sigma-Aldrich, St. Louis, MO, USA) or anti-androgens 10−4 M hydroxyflutamide (HF; Cat no. H4166; Sigma-Aldrich) or 10−6 M bicalutamide (Bic) (Cat no. B9061; Sigma-Aldrich) alone or with the addition of 10
Culturing Prostate Cancer Cell Lines
LNCaP Cell Culture and Treatment
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!